AlphAIAlphAI — Financial news for AI agents
investing.comOCT 291 min read$BMY

Bristol Myers Squibb beats Q3 estimates, raises revenue outlook

Bristol Myers Squibb (BMY) reported Q3 earnings of $1.35 per share, beating estimates by $0.26, with revenue of $13.07B, up 7% YoY. The company raised its 2026 revenue outlook to $49.75B-$50.25B but lowered EPS guidance to $6.35-$6.55. Shares rose over 2%. Growth Portfolio revenues increased 12%, while Legacy Portfolio revenues rose 1%.

Original reporting
investing.com
Published Oct 29, 2026, 11:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BMY
Bullish
high confidence
Mentioned
$BMY
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The earnings beat and raised revenue outlook are likely to drive short‑term buying interest, while the slight EPS guidance miss may temper enthusiasm.

02

Market read

A large‑cap pharma beat with guidance lift provides a clear trading catalyst for BMY and potentially the healthcare sector.

03

What to watch

The -$0.60 EPS impact from IPRD charges could signal future cost headwinds.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Bristol Myers Squibb (BMY) released its third‑quarter 2026 earnings, surpassing analyst expectations and updating its full‑year guidance.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers Squibb reported Q3 earnings beating estimates and raised full-year revenue guidance.

Expected impact

upward pressure as investors price in better-than-expected results and higher guidance

Evidence & confidence

The company posted $13.07B revenue vs $12.72B estimate and EPS $1.35 vs $1.09, with shares already up >2%.

Market effects

Sector

Strong pharma earnings may lift the broader healthcare sector.

Regional

U.S. market sentiment boosted by a large‑cap biotech beat.

Global

BMY's results could influence global biotech sentiment and competitor valuations.

Counterpoint

What could challenge this read

If the EPS guidance miss relative to consensus raises concerns about margin pressure.

Key entities

  • company
    Bristol Myers Squibb

    Pharmaceutical company reporting Q3 results.

Read at source← All news

StoryBristol‑Myers Squibb posts Q3 beat, lifts 2026 revenue outlook and trims full‑year EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$LLYMed

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

finance.yahoo.com2 min
OCT 29
$NVSLow

4 Long-Term Survival Results From ESMO 2026 Patients Should Know

Novartis reported 6-year data from the NATALEE trial showing Kisqali (ribociclib) reduced death risk by 19% in early breast cancer. Merck's Keytruda (pembrolizumab) showed 7-year survival benefits in kidney cancer. Bristol-Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated lasting survival in colorectal cancer. Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combinations showed 3-year survival gains in stomach/esophageal cancer. All treatments were FDA-approved previously.

curetoday.com3 min
OCT 29
$BMYMedAI 8/10

BMS Flounders As Opdivo Lags, Earnings Guidance Cut

Bristol Myers Squibb (BMY) reported Q3 adjusted earnings of $1.35 per share, beating estimates of $1.10, with revenue of $13.07B, also exceeding expectations. The company cut its full-year earnings guidance due to weaker-than-expected sales of its cancer drug, Opdivo. BMY shares declined on the news.

investors.com2 min